Pancreatic Cancer Research

ResearcherUniversité de MontpellierActive in the last 2 years

Fabienne Portales

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1501-5072; OpenAlex author ID A5062386889, A5113879360, A5114026995. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 6 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers

Papers 18

  1. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  2. GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRIN… Co-author DOI 10.1136/bmjopen-2025-104228↗
  3. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  4. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  5. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  6. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcino… Co-author DOI 10.1002/ijc.33225↗
  7. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinica… Co-author DOI 10.1016/j.esmoop.2021.100318↗
  8. Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After … Co-author DOI 10.1245/s10434-020-08740-y↗
  9. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … First author DOI 10.1016/j.ejca.2019.10.020↗
  10. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… First author DOI 10.1016/j.ejca.2020.02.004↗
  11. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Co-author DOI 10.1016/s2468-1253(19)30327-9↗
  12. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  13. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-0950↗
  14. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  15. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  16. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  17. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODI… Co-author DOI 10.1186/s12885-018-4663-4↗
  18. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "TH… Co-author DOI 10.18632/oncotarget.3473↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 7 shared papers, 2018–2025 · strength 0.66
  2. Pascal R. Hammel · 7 shared papers, 2018–2025 · strength 0.66
  3. Marc Ychou · 4 shared papers, 2015–2025 · strength 0.59
  4. Eric Assénat · 4 shared papers, 2015–2025 · strength 0.59
  5. Olivier Bouché · 4 shared papers, 2018–2025 · strength 0.39
  6. Christelle de la Fouchardière · 4 shared papers, 2020–2021 · strength 0.38
  7. Christophe Tournigand · 3 shared papers, 2020–2025 · strength 0.33
  8. David Tougeron · 3 shared papers, 2020–2025 · strength 0.33
  9. Iman El Hariry · 3 shared papers, 2020 · strength 0.27
  10. Jerome F. Cros · 3 shared papers, 2020 · strength 0.27
  11. Roberto Pazo-Cid · 2 shared papers, 2020–2025 · strength 0.25
  12. Eric Van Cutsem · 2 shared papers, 2020–2025 · strength 0.24
  13. Teresa Mercade Macarulla · 2 shared papers, 2020–2025 · strength 0.24
  14. António Sá Cunha · 3 shared papers, 2018–2019 · strength 0.23
  15. Roger Faroux · 2 shared papers, 2020 · strength 0.17
  16. Thierry André · 2 shared papers, 2020 · strength 0.17
  17. Christophe Louvet · 2 shared papers, 2020 · strength 0.17
  18. Jean‐Luc Van Laethem · 1 shared paper, 2025 · strength 0.16
  19. Mariano Ponz‐Sarvisé · 1 shared paper, 2025 · strength 0.16
  20. Rocio García‐Carbonero · 1 shared paper, 2025 · strength 0.16
  21. Rossana Berardi · 1 shared paper, 2025 · strength 0.16
  22. Isabelle Trouilloud · 1 shared paper, 2025 · strength 0.16
  23. Manuel M. Hidalgo · 1 shared paper, 2025 · strength 0.16
  24. Marcus Smith Noel · 1 shared paper, 2025 · strength 0.16
  25. Jaime Feliú · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.